middle.news
Syntara Accelerates Clinical Trials and Secures Key EMA Orphan Drug Status
10:34am on Thursday 29th of January, 2026 AEDT
•
Healthcare
Read Story
Syntara Accelerates Clinical Trials and Secures Key EMA Orphan Drug Status
10:34am on Thursday 29th of January, 2026 AEDT
Key Points
Initiation of Phase 2 MESSAGE trial for amsulostat in transfusion-dependent MDS
Positive European Medicines Agency opinion for orphan drug designation in myelofibrosis
Completion of recruitment in Phase 2 iRBD trial with milestone payment triggered
Progression of topical anti-fibrotic SNT-9465 into Phase 1b hypertrophic scar study
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
SYNTARA (ASX:SNT)
OPEN ARTICLE